Skip to main content
Log in

Melatonin—Aluminum Oxide—Polymethylsiloxane Complex on Apoptosis of Liver Cells in a Model of Obesity and Type 2 Diabetes Mellitus

  • Published:
Bulletin of Experimental Biology and Medicine Aims and scope

We studied the effects of a melatonin—aluminum oxide—polymethylsiloxane complex (complex M) on the expression of apoptosis regulators Bcl-2 and Bad in the liver of homozygous db/db BKS.Cg-Dock7m+/+Leprdb/J mice with obesity and type 2 diabetes. Complex M or placebo was administered daily through the gastric tube during weeks 8-16 of life. In mice with type 2 diabetes mellitus receiving placebo, enhanced immunohistochemical reactions for proapoptotic Bad protein and weak response for anti-apoptotic Bcl-2 protein were observed. Administration of complex M shifted the ratio of apoptosis regulators: the area of Bcl-2 expression significantly increased and against the background of reduced Bad expression area. These findings attest to antiapoptotic effect of complex M in the liver on the model of type 2 diabetes mellitus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others


  1. Konenkov VI, Klimontov VV, Michurina SV, Prudnikova MA, Ishenko IJu. Melatonin and diabetes: from pathophysiology to the treatment perspectives. Sakhar. Diabet. 2013;(2):11-16. Russian.

  2. Michurina SV, Ishchenko IY, Arkhipov SA, Klimontov VV, Rachkovskaya LN, Konenkov VI, Zavyalov EL. Effects of Melatonin, Aluminum Oxide, and Polymethylsiloxane Complex on the Expression of LYVE-1 in the Liver of Mice with Obesity and Type 2 Diabetes Mellitus. Bull. Exp. Biol. Med. 2016;162(2):269-272.

    Article  CAS  PubMed  Google Scholar 

  3. Michurina SV, Rachkovskaja LN, Ishchenko IJ, Rachkovskij EE, Klimontov VV, Konenkov VI. Patent RU No. 2577580. Alumina-based porous sorbent with chronotropic properties. Bull. No. 8. Published March 20, 2016.

  4. Agil A, El-Hammadi M, Jiménez-Aranda A, Tassi M, Abdo W, Fernández-Vázquez G, Reiter RJ. Melatonin reduces hepatic mitochondrial dysfunction in diabetic obese rats. J. Pineal Res. 2015;59(1):70-79.

    Article  CAS  PubMed  Google Scholar 

  5. de Luxán-Delgado B, Potes Y, Rubio-González A, Caballero B, Solano JJ, Fernández-Fernández M, Bermúdez M, Rodrigues Moreira Guimarães M, Vega-Naredo I, Boga JA, Coto-Montes A. Melatonin reduces endoplasmic reticulum stress and autophagy in liver of leptin-deficient mice. J. Pineal. Res. 2016;61(1):108-123.

    Article  PubMed  Google Scholar 

  6. Hatzis G, Ziakas P, Kavantzas N, Triantafyllou A, Sigalas P, Andreadou I, Ioannidis K, Chatzis S, Filis K, Papalampros A, Sigala F. Melatonin attenuates high fat diet-induced fatty liver disease in rats. World J. Hepatol. 2013;5(4):160-169.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Hu S, Yin S, Jiang X, Huang D, Shen G. Melatonin protects against alcoholic liver injury by attenuating oxidative stress, inflammatory response, and apoptosis. Eur. J. Pharmacol. 2009;616(1-3):287-292.

    Article  CAS  PubMed  Google Scholar 

  8. Kireev R, Bitoun S, Cuesta S, Tejerina A, Ibarrola C, Moreno E, Vara E, Tresguerres JA. Melatonin treatment protects liver of Zucker rats after ischemia/reperfusion by diminishing oxidative stress and apoptosis. Eur. J. Pharmacol. 2013;701(1-3):185-193.

    Article  CAS  PubMed  Google Scholar 

  9. Michurina SV, Ishenko IJ, Klimontov VV, Archipov SA, Myakina NE, Cherepanova MA, Zavjalov EL, Koncevaya GV, Konenkov VI. Linagliptin alleviates fatty liver disease in diabetic db/db mice. World J. Diabetes. 2016;7(19):534-546.

    Google Scholar 

  10. Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J. Gastroenterol. Hepatol. 2013;28(Suppl. 1):68-76.

    Article  CAS  PubMed  Google Scholar 

  11. Sheen JM, Chen YC, Hsu MH, Tain YL, Huang YH, Tiao MM, Li SW, Huang LT. Melatonin alleviates liver apoptosis in bile duct ligation young rats. Int. J. Mol. Sci. 2016;17(8):pii: E1365. doi: 10.3390/ijms17081365.

  12. Stacchiotti A, Favero G, Lavazza A, Golic I, Aleksic M, Korac A, Rodella LF, Rezzani R. Hepatic macrosteatosis is partially converted to microsteatosis by melatonin supplementation in ob/ob mice non-alcoholic fatty liver disease. PLoS One. 2016;11(1):e0148115. doi:

    Article  PubMed  PubMed Central  Google Scholar 

  13. Sun H, Wang X, Chen J, Song K, Gusdon AM, Li L, Bu L, Qu S. Melatonin improves non-alcoholic fatty liver disease via MAPK-JNK/P38 signaling in high-fat-diet-induced obese mice. Lipids Health Dis. 2016;15(1):202.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Zavodnik IB, Lapshina EA, Cheshchevik VT, Dremza IK, Kujawa J, Zabrodskaya SV, Reiter RJ. Melatonin and succinate reduce rat liver mitochondrial dysfunction in diabetes. J. Physiol. Pharmacol. 2011;62(4):421-427.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to S. V. Michurina.

Additional information

Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 164, No. 8, pp. 192-196, August, 2017

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Michurina, S.V., Ischenko, I.Y., Arkhipov, S.A. et al. Melatonin—Aluminum Oxide—Polymethylsiloxane Complex on Apoptosis of Liver Cells in a Model of Obesity and Type 2 Diabetes Mellitus. Bull Exp Biol Med 164, 165–169 (2017).

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI:

Key Words